- Open Access
The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer
© Matsushita et al.; licensee BioMed Central Ltd. 2014
- Received: 7 October 2014
- Accepted: 2 November 2014
- Published: 26 November 2014
The human RECQ DNA helicase family is involved in genomic stability. Gene mutations of RECQL2, RECQL3, and RECQL4 are associated with genetic disorders and induce early aging and carcinogenesis. Although previous studies have reported that the level of RECQL1 expression is correlated with the prognosis of some of malignancies, the function of RECQL1 is not yet clarified. The present study aimed to examine the relationship between prognosis and the level of RECQL1 expression in epithelial ovarian cancer (EOC), and to identify the role of RECQL1 in EOC cells.
The level of RECQL1 expression was determined immunohistochemically in 111 patients with EOC who received initial treatment at Hirosaki University hospital between 2006 and 2011. Effects of RECQL1 on cell growth or apoptosis were examined in vitro using wild-type and OVCAR-3 cells (RECQL1(+) cells) and similar cells transfected with RECQL1 siRNA transfected (RECQL1(−) cells).
The level of RECQL1 expression was not related to histological type, clinical stage, or retroperitoneal lymph node metastasis, but the expression level was significantly higher (P = 0.002) in patients with recurrence than those without recurrence, and progression-free survival and complete response rate to chemotherapy were also improved in patients with RECQL1-low expression (n = 39) stage III/IV EOC (P = 0.02 and P <0.05 vs RECQL1-high expression patients (n = ), respectively). A cell proliferation and colony formation assays revealed significantly less growth of RECQL1(−) cells compared to RECQL1(+) cells. A flow cytometry using annexin V -FITC and propidium iodide (PI) staining revealed a significant increase in apoptotic RECQL1(−) cells. Cell cycle analysis showed a significantly greater distribution in subG1 phase indicating apoptotic cells in RECQL1(−) cells than in RECQL1(+) cells.
These results suggest that RECQL1 is a prognostic factor for EOC and that RECQL1 contributes to potential malignancy by inhibiting apoptosis.
- Ovarian cancer
Epithelial ovarian cancer (EOC) is the world’s most lethal gynecological cancer and the World Health Organization Global database listed EOC as the seventh leading form of cancer in women in 2008 .
Although the mean 5-year survival rate for EOC has improved significantly over the past 30 years, the prognosis remains poor, with a 46% 5-year survival rate . The prognosis for EOC is closely related to the clinical stage of the cancer at diagnosed. The mean 5-year survival rate in advanced stages (FIGO stage III or IV) is as low as 11% to 41% . More than 70% of EOC is detected in the advanced stages mainly because of a lack of early warning signs and of reliable diagnostic tests. Cytoreductive surgery followed by adjuvant chemotherapy is recommended as the primary treatment for advanced EOC. Postoperatively, the combination of a taxane and carboplatin is used as first-line chemotherapy. EOC is highly responsive to initial anticancer treatment, but approximately half of the advanced cases recur within two years and result in poor prognosis due to a decreased response to chemotherapy . Therefore, new clinically useful biomarkers and new targets for treatment of EOC need to be identified so as to initiate intensive treatment.
Initially found in Escherichia coli, RECQ helicase affects the recombination of DNA, and deletion of RECQ helicase causes genomic instability . In addition, deletion of a RECQ helicase SGS1 induces genomic instability in yeast and shortens its life by increasing the sensitivity to drugs that react with DNA . There are five types of RECQ helicase in humans: RECQL1, WRN, BLM, RTS, and RECQ5 . WRN, BLM, and RTS are involved in genetic disorders associated with genomic instability and a high incidence of cancer -. However, the function of RECQL1 in regulation of cancer growth is not fully clarified. A recent study has indicated that RECQL1, a typical member of the RECQL family  unwinds DNA and plays a role in chromosomal stability . Earlier studies have shown a relationship between the level of expression or mutation of RECQL1 and the prognosis for pancreatic cancer, liver cancer, and head and neck cancer -. More recent study has suggested a significant role of RECQL1 as a proliferative marker in EOC .
The present study examined the relationship between prognosis and the level of RECQL1 expression in EOC. This study also identified the role of RECQL1 in cancer cells.
Subjects and tissue samples
Number of patients
Age (Median, range) yr
Clear cell adenocarcinoma
Retroperitoneal lymph node involvement
< 1.0 cm
≥ 1.0 cm
Cell line and cell cultures
OVCAR-3 was obtained from the American Type Culture Collection (Rockville, MD). This cell line is derived from human ovarian papillary adenocarcinoma and was grown in RPMI 1640 supplemented with 10% FCS at 37°C in a water-saturated atmosphere with 5% CO2/95% air. OVCAR-3 was verified in writing as being ovarian in origin. OVCAR-3 overexpresses RECQL1 .
siRNA and RNA interference
siRNA (21 bp) targeting RECQL1 mRNA (RECQL1-siRNA) and negative (non-silencing) control siRNA were chemically synthesized using FlexiTube GeneSolution GS5965 for RECQL (QIAGEN, Tokyo, Japan). Cells were transfected with RECQL1-siRNA for 48 hours at a final concentration of 10 nM siRNA using the Hyperfect transfection system (QIAGEN) in accordance with the manufacturer’s instructions. All siRNA sequences had overhanging-3′-TT. siRNA sequences were as follows:
RECQL1 siRNA sense sequence (5′-CAUUGAUCUCUCUUAUGGAtt -3′),
RECQL1 siRNA antisense sequence (3′-ggGUAACUAGAGAGAAUACCU -5′),
control siRNA sense sequence (5′-AGGUCGAGAUGACAUGAAAtt -3′), and
control siRNA antisense sequence (3′- ggUCCAGCUCUACUGUACUUU -5′).
Real-time quantitative PCR
Total RNA was extracted from cells using an Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare, Piscataway, NJ). Total RNA (5 μg) served as a template for single-strand cDNA synthesis in a reaction using an iScript Advanced cDNA Kit (Bio-Rad, Hercules, CA) under previously described conditions  with slight modifications. A CFX96 real-time PCR detection system (Bio-Rad) was used for quantitative analyses of RECQL1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primer sequences were as follows:
RECQL1-R (5′- GGAACTGCCGCTTTAAGATACCAA-3′)
GAPDH-F (5′-CCTCCCGCTTCGCTCTCT -3′), and
GAPDH-R (5′- GCTGGCGACGCA AAAGA -3′)
The primers were used at a concentration of 300 nM. Amplification conditions were as follows: 30 seconds at 95°C, followed by 95°C for 5 seconds, and 60°C for 30 seconds for 40 consecutive cycles. After amplification, a melting curve from 65°C to 95°C at 0.5°C increments and 5 seconds per step was generated with continuous monitoring of fluorescence. CFX manager Version 2.1 software (Bio-Rad) was used to create the melting curves and quantitatively analyze data. The level of RECQL1 mRNA in a sample was normalized to that of GAPDH mRNA.
Western blot analysis
Cell lysates (50 μg protein) were prepared from OVACAR-3 cells transfected with RECQL1-siRNA or control siRNA (as control), electrophoresed through a 12.5% sodium dodecyl sulfate polyacrylamide gel, and blotted as described previously . The protein concentration was determined using Bradford’s method. The blots were probed with the following diluted antibodies for 2 hours: RECQL1 (Santa Cruz Biotechnology) at 1:1000 and β-actin (Sigma-Aldrich, St Louis, MO)) at 1:2000. The membranes were then incubated for 1 hour with the appropriate biotinylated secondary antibodies, transferred to avidin-biotin-peroxidase complex reagent, and incubated in this solution for 30 minutes. DAB was used as a substrate.
OVCAR-3 cells (1 × 104 cells) were cultured in 6-well plates as described in Cell line and cell culture. Cell counts were performed 24 hours, 48 hours and 72 hours after OVACAR-3 cells were transfected with RECQL1-siRNA or control siRNA (as control). To distinguish live and dead cells, cells were stained with 0.3% trypan blue solution (Wako Pure Chemical Industries, Osaka, Japan). Cells were counted in a hemocytometer. The cell count was performed in triplicate, and the total cell count and the number of dead cells were represented as averages.
Colony formation assay
Single-cell suspensions (50 cells) of OVCAR-3 in RPMI1640 (10% FBS) were seeded in 6-well plates. OVCAR-3 cultures were fixed in 6% glutaraldehyde and stained with 0.5% crystal violet at day 7 . The stained cultures were analyzed by microscopy, and aggregates containing 50 or more cells were counted as colonies. The number of colonies per well was counted. This assay was performed in triplicate.
Determination of apoptotic cells
Apoptotic or necrotic cells were determined using flow cytometry with an Annexin V-FITC kit (Beckman Coulter, Fullerton, CA). Cells were harvested and washed with cold PBS. Cells were re-suspended with 100 μL annexin-V binding buffer and then incubated with 10 μL annexin-V for 15 min at room temperature in darkness. Four hundred μL binding buffer containing 5 μL propidium iodide (PI) was added to the cells and cells were incubated on ice for 15 min. The cells were applied to a FACS Calibur-500 flow cytometer within 1 hr of preparation. A total of 1 × 104 cells were analyzed in each sample. Evaluation was done 24 hours after transfection of RECQL1-siRNA or control siRNA. The results were interpreted as follows: Cells that were annexin V(−)/PI(−) (lower left quadrant) were considered as living cells; annexin V(+)/PI(−) (lower right quadrant) as apoptotic cells; annexin V(+)/PI(+) (upper right quadrant) as necrotic cells; and annexin V(−)/PI(+) (upper left quadrant) may be bare nuclei, cells in late necrosis, or cellular debris. Experiments were repeated in triplicate.
Cell cycle analysis
Cell cycle was determined using flow cytometry with a Cell cycle phase determination kit (Cayman Chemical, Ann Arbor, MI). For the cell cycle assay, 1 × 105 cells were seeded in 6-well plate. Evaluation was done 24 hours after transfection of RECQL1-siRNA or control siRNA. Cells were harvested and fixed gently by adding 75% ethanol and placing at −20°C for 4–16 h. The cells were washed twice with PBS, resuspended in 300 μl PBS containing 100 μg/ml PI and 0.1 mg/ml RNase, incubated for 30 min at room temperature in dark, and analyzed using a flow cytometer. FlowJo 7.1.0 software (Tree Star, Ashland, OR) was used for data analysis and at least 10,000 cells were counted for each measurement. Experiments were repeated in triplicate.
All statistical analyses were performed using SPSS (version 21, SPSS Inc., Chicago, IL, USA). Differences in staining scores due to clinico-pathological factors were analyzed using a chi-square test. Progression-free survival (PFS) was defined as the period from the end of the first-line regimen to initiation of the second-line regimen after signs of recurrence were verified in imaging. Overall survival (OS) was calculated from the date of the start of treatment to the date of death or last follow-up. Cumulative survival curves were estimated using the Kaplan-Meier method. Survival curves were compared using the log-rank test. Variables with effect on PFS in univariate analysis were included in the Cox proportional hazard regression model. Multivariate logistic regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs) after controlling simultaneously for potential confounders. Variables considered in the models were age, histological types, residual tumor, lymph node status and RECQL1 expression status. Other differences were analyzed by Student’s t-test. Statistical significance was set at P <0.05.
Relationship between clinicopathological factors and the level of RECQL1 expression
Relationship between clinico-pathological factors and RECQL1 expression
Number of patients
RECQL1- high expression
Clear cell adenocarcinoma
Retroperitoneal lymph node metastases (n = 53)
P = 0.002
Univariate and multivariate analyses for determining prognostic factors of progression free survival in stage III/IV epithelial ovarian cancer
> 40 (n = 4) vs. ≤40 (n = 42)
Serous (n = 29) vs. non-serous (n = 17)
< 1.0 cm (n = 32) vs. ≥1.0 cm (n = 14)
Lymph nodes status
Negative (n = 16) vs. Positive (n = 14)
RECQL1 expression status
High (n = 7) vs. Low (n = 39)
Relationship between the level of RECQL1 expression and the sensitivity to anticancer drugs
Relationship between chemo-sensitivity and RECQL1 expression
Response to chemotherapy
Number of patients
RECQL1- high expression
Transfection efficiency of siRNA targeting RECQL1
Comparison of the growth of RECQL1(−) and RECQL1(+) cells
Comparison of apoptosis in RECQL1(−) and RECQL1(+) cells
Results of fluorescent double staining of cell membranes and nuclei analyzed by flow cytometry
Fluorescent double staining
Annexin V(−)/PI(−) (Live cells)
9133 ± 93.0
8863 ± 121.3
Annexin V(+)/PI(−) (Apoptotic cells)
160 ± 10.0
427 ± 42.3
Comparison of cell cycle distribution in RECQL1(−) and RECQL1(+) cells
Although significant association was not found between levels of RECQL1 expression and clinical background such as histological type, clinical stage, and retroperitoneal lymph node metastasis, the results of the present study have shown a close relationship between the recurrence of EOC and the level of RECQL1 expression. In addition, PFS of patients with RECQL1-high EOC was significantly shorter than that of RECQL1-low patients at stage III/IV EOC. Previous studies have shown that RECQL1 is expressed at high levels in cancer cells with rapid growth, while RECQL1 is expressed at low levels in cells at resting stage . In addition, the higher level of expression of RECQL1 is shown in hepatic cancer at high grade . Because non-malignant liver tissue has slight staining, it is proposed that RECQL1 can be a molecular marker that predicts malignancies and progression of liver cancer . Sanada et al. demonstrated that high expression of RECQL1 is correlated with a high Ki-67 labeling index and that it can be a marker of high proliferation in ovarian cancer tissue . Although we did not examine the relationship between expression of RECQL1 and cell growth such as Ki-67 labeling index in our subjects, we showed that high expression of RECQL1 was correlated with a significantly shorter PFS in stage III/IV EOC. Recurrence is a critical issue that worsens prognosis. Therefore, determination of RECQL1 can be a useful marker for planning strategy of tailor-made treatment.
The present study showed a close relationship between a high level of RECQL1 expression and resistance to chemotherapy in stage III/IV EOC. All patients with EOC in this study received combined chemotherapy with TC after surgery. Zhang et al. have shown that RECQL1 is expressed at high levels in cisplatin-resistant cancer cell lines derived from moderately-differentiated tongue squamous cell carcinoma, and they proposed that RECQL1 may be associated with the acquisition of cisplatin resistance . The formation of DNA adducts by cisplatin results in apoptosis, and several studies have shown that apoptosis is attenuated in cells with extensive DNA repair ,. Although the EOC patients used in this study were treated with carboplatin, a platinum analogue like cisplatin, expression of RECQL1 is shown to be involved in chemo-resistance and the results of present study support previous findings that high expression of RECQL1 attenuates the effectiveness of platinum analogues .
In order to clarify the biological significance of RECQL1 expression in cell growth, RECQL1 siRNA was transfected into OVCAR-3 cells. As shown in Figures 4, 5, and 6 and Table 5, RECQL1 siRNA transfected-cells significantly reduced cell growth and increased apoptosis compared to those of control cells. An earlier study showed increased mitotic death (mitotic catastrophe) was prominent in a number of cancer cells transfected with RECQL1 siRNA . Mitotic catastrophe occurs once the cell division cycle that is not repaired by RECQL1 reaches the M phase. In addition, if cancer cells expressing high levels of DNA repair enzymes such as RECQL1 are affected by specific and rapid silencing via RECQL1 siRNA, cancer cells retaining DNA abnormalities proceed to the M phase of the cell division cycle and mitotic arrest (mitotic catastrophe) occurs in the M phase. However, the present study did not show an increased cell distribution of the M phase in which mitotic catastrophe occurs in RECQL1 siRNA transfected-cells. It is suggested in this study that OVCAR-3 cells with decreased RECQL1 expression yielded to apoptosis. Arai et al. reported that transfection of RECQL1 siRNA in the presence of cisplatin caused apoptosis of cancer cells . Ngan et al. indicated that the anticancer drug oxaliplatin causes both mitotic catastrophe and apoptosis . Although the mechanisms of cell death, including apoptosis, mitotic catastrophe, and necrosis, still need to be elucidated , results of the present study suggest that silencing RECQL1 induces apoptosis.
In earlier studies, reduction of RECQL1 expression in cancer cells through using siRNA showed an inhibitory effect on growth of cancer in vivo ,. In contrast, normal cells were not affected by the silencing of RECQL1 . This fact may signal a breakthrough for a new strategy to treat malignant tumors including ovarian cancer. Induction of apoptosis is an important part of designing anticancer drugs. RECQL1 induces apoptosis, so drug discovery targeting RECQL1 is a promising area for future research.
This study was supported by a Grant-in Aid for Cancer Research (No. 20591935) from the Ministry of Education, Science and Culture of Japan.
- Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013,63(1):11–30. 10.3322/caac.21166View ArticlePubMedGoogle Scholar
- Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U: Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006, 95: S161-S192. 10.1016/S0020-7292(06)60033-7View ArticlePubMedGoogle Scholar
- Yokoyama Y, Futagami M, Watanabe J, Sato N, Terada Y, Miura F, Sugiyama T, Takano T, Yaegashi N, Kojimahara T, Kurachi H, Nishiyama H, Fujimori K, Tase T, Mizunuma H: Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. Mol Clin Oncol 2014,2(2):212–218.PubMed CentralPubMedGoogle Scholar
- Nakayama H, Nakayama K, Nakayama R, Irino N, Nakayama Y, Hanawalt PC: Isolation and genetic characterization of a thymineless death-resistant mutant of Escherichia coli K12: identification of a new mutation (recQ1) that blocks the RecF recombination pathway. Mol Gen Genet 1984,195(3):474–480. 10.1007/BF00341449View ArticlePubMedGoogle Scholar
- Sinclair DA, Guarente L: Extrachromosomal rDNA circles–a cause of aging in yeast. Cell 1997,91(7):1033–1042. 10.1016/S0092-8674(00)80493-6View ArticlePubMedGoogle Scholar
- Furuichi Y: Premature aging and predisposition to cancers caused by mutations in RecQ family helicases. Ann N Y Acad Sci 2001, 928: 121–131. 10.1111/j.1749-6632.2001.tb05642.xView ArticlePubMedGoogle Scholar
- Kitao S, Shimamoto A, Goto M, Miller RW, Smithson WA, Lindor NM, Furuichi Y: Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet 1999,22(1):82–84. 10.1038/8788View ArticlePubMedGoogle Scholar
- Hickson ID, Davies SL, Li JL, Levitt NC, Mohaghegh P, North PS, Wu L: Role of the Bloom's syndrome helicase in maintenance of genome stability. Biochem Soc Trans 2001, 29: 201–204. 10.1042/BST0290201View ArticlePubMedGoogle Scholar
- Watt PM, Hickson ID, Borts RH, Louis EJ: SGS1, a homologue of the Bloom’s and Werner’s syndrome genes, is required for maintenance of genome stability in Saccharomyces cerevisiae. Genetics 1996,144(3):935–945.PubMed CentralPubMedGoogle Scholar
- Seki M, Miyazawa H, Tada S, Yanagisawa J, Yamaoka T, Hoshino S, Ozawa K, Eki T, Nogami M, Okumura K, Taguchi H, Hanaoka F, Enomoto T: Molecular cloning of cDNA encoding human DNA helicase Q1 which has homology to Escherichia coli Rec Q helicase and localization of the gene at chromosome 12p12. Nucleic Acids Res 1994,22(22):4566–4573. 10.1093/nar/22.22.4566PubMed CentralView ArticlePubMedGoogle Scholar
- Thangavel S, Mendoza-Maldonado R, Tissino E, Sidorova JM, Yin J, Wang W, Monnat RJ Jr, Falaschi A, Vindigni A: Human RECQ1 and RECQ4 helicases play distinct roles in DNA replication initiation. Mol Cell Biol 2010,30(6):1382–1396. 10.1128/MCB.01290-09PubMed CentralView ArticlePubMedGoogle Scholar
- Futami K, Kumagai E, Makino H, Sato A, Takagi M, Shimamoto A, Furuichi Y: Anticancer activity of RecQL1 helicase siRNA in mouse xenograft models. Cancer Sci 2008,99(6):1227–1236. 10.1111/j.1349-7006.2008.00794.xView ArticlePubMedGoogle Scholar
- Futami K, Ogasawara S, Goto H, Yano H, Furuichi Y: RecQL1 DNA repair helicase: a potential tumor marker and therapeutic target against hepatocellular carcinoma. Int J Mol Med 2010,25(4):537–545.PubMedGoogle Scholar
- Arai A, Chano T, Futami K, Furuichi Y, Ikebuchi K, Inui T, Tameno H, Ochi Y, Shimada T, Hisa Y, Okabe H: RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma. Cancer Res 2011,71(13):4598–4607. 10.1158/0008-5472.CAN-11-0320View ArticlePubMedGoogle Scholar
- Sanada S, Futami K, Terada A, Yonemoto K, Ogasawara S, Akiba J, Yasumoto M, Sumi A, Ushijima K, Kamura T, Furuichi Y, Yano H: RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer. PLoS One 2013,8(8):e72820. 10.1371/journal.pone.0072820PubMed CentralView ArticlePubMedGoogle Scholar
- Yoshida H, Meng P, Matsumiya T, Tanji K, Hayakari R, Xing F, Wang L, Tsuruga K, Tanaka H, Mimura J, Kosaka K, Itoh K, Takahashi I, Imaizumi T: Carnosic acid suppresses the production of amyloid-β 1–42 and 1–43 by inducing an α-secretase TACE/ADAM17 in U373MG human astrocytoma cells. Neurosci Res 2014, 79: 83–93. 10.1016/j.neures.2013.11.004View ArticlePubMedGoogle Scholar
- Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 2006,1(5):2315–2319. 10.1038/nprot.2006.339View ArticlePubMedGoogle Scholar
- Kawabe T, Tsuyama N, Kitao S, Nishikawa K, Shimamoto A, Shiratori M, Matsumoto T, Anno K, Sato T, Mitsui Y, Seki M, Enomoto T, Goto M, Ellis NA, Ide T, Furuichi Y, Sugimoto M: Differential regulation of human RecQ family helicases in cell transformation and cell cycle. Oncogene 2000,19(41):4764–4772. 10.1038/sj.onc.1203841View ArticlePubMedGoogle Scholar
- Zhang P, Zhang Z, Zhou X, Qiu W, Chen F, Chen W: Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer 2006, 6: 224. 10.1186/1471-2407-6-224PubMed CentralView ArticlePubMedGoogle Scholar
- Mimnaugh EG, Yunmbam MK, Li Q, Bonvini P, Hwang SG, Trepel J, Reed E, Neckers L: Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors. Biochem Pharmacol 2000,60(9):1343–1354. 10.1016/S0006-2952(00)00455-XView ArticlePubMedGoogle Scholar
- Nyberg KA, Michelson RJ, Putnam CW, Weinert TA: Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 2002, 36: 617–656. 10.1146/annurev.genet.36.060402.113540View ArticlePubMedGoogle Scholar
- Ngan CY, Yamamoto H, Takagi A, Fujie Y, Takemasa I, Ikeda M, Takahashi-Yanaga F, Sasaguri T, Sekimoto M, Matsuura N, Monden M: Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci 2008,99(1):129–139.PubMedGoogle Scholar
- de Bruin EC, Medema JP: Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev 2008,34(8):737–749. 10.1016/j.ctrv.2008.07.001View ArticlePubMedGoogle Scholar
- Tao J, Tao S, Han J, Zhou Z, Zhang X, Wang H, Chen R, Ji F, Zhu Y: RECQL1 plays an important role in the development of tongue squamous cell carcinoma. Cell Physiol Biochem 2014,33(5):1579–1590. 10.1159/000358721View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.